[{"id":"31764096-6379-4314-a6a8-370698657726","acronym":"","url":"https://clinicaltrials.gov/study/NCT02226276","created_at":"2021-01-18T10:26:21.550Z","updated_at":"2025-02-25T14:14:41.067Z","phase":"","brief_title":"Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer","source_id_and_acronym":"NCT02226276","lead_sponsor":"City of Hope Medical Center","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 positive + HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 positive + HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Kadcyla (ado-trastuzumab emtansine)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 01/07/2015","start_date":" 01/07/2015","primary_txt":" Primary completion: 12/07/2021","primary_completion_date":" 12/07/2021","study_txt":" Completion: 10/30/2025","study_completion_date":" 10/30/2025","last_update_posted":"2025-02-18"},{"id":"742fd153-ce97-4ee4-b30a-065c666ab97f","acronym":"UNICORN","url":"https://clinicaltrials.gov/study/NCT05845450","created_at":"2023-05-06T15:04:38.828Z","updated_at":"2025-02-25T14:09:41.563Z","phase":"Phase 2","brief_title":"Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)","source_id_and_acronym":"NCT05845450 - UNICORN","lead_sponsor":"Gruppo Oncologico del Nord-Ovest","biomarkers":" HER-2 • KRAS • BRAF • TMB • MSI • POLE • POLD1","pipe":" | ","alterations":" HER-2 positive • MSI-H/dMMR • KRAS G12C • HER-2 amplification • HER-2 mutation • POLE mutation • KRAS wild-type • RAS wild-type • KRAS G12 • POLD1 mutation • HER-2 positive + HER-2 overexpression • HER-2 positive + RAS wild-type","tags":["HER-2 • KRAS • BRAF • TMB • MSI • POLE • POLD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • MSI-H/dMMR • KRAS G12C • HER-2 amplification • HER-2 mutation • POLE mutation • KRAS wild-type • RAS wild-type • KRAS G12 • POLD1 mutation • HER-2 positive + HER-2 overexpression • HER-2 positive + RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Vectibix (panitumumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Lumakras (sotorasib) • balstilimab (AGEN2034) • botensilimab (AGEN1181)"],"overall_status":"Recruiting","enrollment":" Enrollment 112","initiation":"Initiation: 05/11/2023","start_date":" 05/11/2023","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2025-02-17"},{"id":"8246cf27-0853-4b25-adbc-f7d54fbbd62d","acronym":"NCI-2016-00570","url":"https://clinicaltrials.gov/study/NCT02827877","created_at":"2021-01-18T13:51:54.989Z","updated_at":"2025-02-25T14:01:03.457Z","phase":"Phase 2","brief_title":"Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer","source_id_and_acronym":"NCT02827877 - NCI-2016-00570","lead_sponsor":"City of Hope Medical Center","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 positive + HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 positive + HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Perjeta (pertuzumab) • Trazimera (trastuzumab-qyyp)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 07/15/2016","start_date":" 07/15/2016","primary_txt":" Primary completion: 07/02/2020","primary_completion_date":" 07/02/2020","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2025-01-24"},{"id":"14763699-a9a1-4656-939a-4ccb4819119b","acronym":"BIS-Program","url":"https://clinicaltrials.gov/study/NCT05180006","created_at":"2022-01-06T23:53:44.740Z","updated_at":"2025-02-25T12:28:33.945Z","phase":"Phase 2","brief_title":"Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy","source_id_and_acronym":"NCT05180006 - BIS-Program","lead_sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","biomarkers":" HER-2 • PGR • GZMB","pipe":" | ","alterations":" HER-2 positive • HER-2 overexpression • HER-2 amplification • HER-2 positive + HER-2 overexpression","tags":["HER-2 • PGR • GZMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 overexpression • HER-2 amplification • HER-2 positive + HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Herceptin (trastuzumab) • Tecentriq (atezolizumab) • Perjeta (pertuzumab) • ipatasertib (RG7440)"],"overall_status":"Recruiting","enrollment":" Enrollment 185","initiation":"Initiation: 02/24/2022","start_date":" 02/24/2022","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-04-18"},{"id":"0b41fdfe-9a1f-478b-aa60-e114706459cf","acronym":"RosHER","url":"https://clinicaltrials.gov/study/NCT05217381","created_at":"2022-02-05T18:28:12.227Z","updated_at":"2025-02-25T15:00:15.610Z","phase":"","brief_title":"Real-World Data of Clinicopathological Characteristics and Management of Breast Cancer Patients According to HER2 Status","source_id_and_acronym":"NCT05217381 - RosHER","lead_sponsor":"MedSIR","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • HER-2 expression • HER-2 underexpression • HER-2 positive + HER-2 overexpression","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • HER-2 expression • HER-2 underexpression • HER-2 positive + HER-2 overexpression"],"overall_status":"Completed","enrollment":" Enrollment 18533","initiation":"Initiation: 02/22/2022","start_date":" 02/22/2022","primary_txt":" Primary completion: 09/20/2023","primary_completion_date":" 09/20/2023","study_txt":" Completion: 09/20/2023","study_completion_date":" 09/20/2023","last_update_posted":"2023-09-25"},{"id":"71ac08c4-727c-416e-b980-ffdd3937d912","acronym":"","url":"https://clinicaltrials.gov/study/NCT00206427","created_at":"2021-01-18T00:42:07.673Z","updated_at":"2025-02-25T13:07:55.241Z","phase":"Phase 2","brief_title":"Neoadjuvant GW572016 to Treat Breast Cancer","source_id_and_acronym":"NCT00206427","lead_sponsor":"Baylor Breast Care Center","biomarkers":" EGFR • HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 overexpression • HER-2 positive + HER-2 overexpression","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 overexpression • HER-2 positive + HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lapatinib"],"overall_status":"Completed","enrollment":" Enrollment 49","initiation":"Initiation: 08/01/2004","start_date":" 08/01/2004","primary_txt":" Primary completion: 06/01/2011","primary_completion_date":" 06/01/2011","study_txt":" Completion: 02/01/2012","study_completion_date":" 02/01/2012","last_update_posted":"2021-09-29"},{"id":"86b4d4e0-30f8-4d43-9e4d-4a273c0e4337","acronym":"PHC-BC","url":"https://clinicaltrials.gov/study/NCT04281641","created_at":"2021-01-18T20:47:16.718Z","updated_at":"2025-02-25T13:53:11.358Z","phase":"","brief_title":"Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast Cancer","source_id_and_acronym":"NCT04281641 - PHC-BC","lead_sponsor":"Fudan University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification • HER-2 positive + HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification • HER-2 positive + HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • carboplatin • docetaxel • Perjeta (pertuzumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 94","initiation":"Initiation: 04/21/2020","start_date":" 04/21/2020","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 04/30/2030","study_completion_date":" 04/30/2030","last_update_posted":"2020-05-04"},{"id":"e96be03f-8921-4ee6-aad4-ba970085ea21","acronym":"","url":"https://clinicaltrials.gov/study/NCT01855828","created_at":"2021-01-18T08:17:20.029Z","updated_at":"2025-02-25T14:00:11.848Z","phase":"Phase 2","brief_title":"Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer","source_id_and_acronym":"NCT01855828","lead_sponsor":"Yale University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 overexpression • HER-2 amplification • HER-2 positive + HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 overexpression • HER-2 amplification • HER-2 positive + HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • 5-fluorouracil • Perjeta (pertuzumab) • cyclophosphamide • epirubicin • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 09/01/2013","start_date":" 09/01/2013","primary_txt":" Primary completion: 08/01/2018","primary_completion_date":" 08/01/2018","study_txt":" Completion: 08/01/2018","study_completion_date":" 08/01/2018","last_update_posted":"2020-03-31"},{"id":"385a9020-3773-4d4a-8b59-47e8d42511ac","acronym":"TBCRC 006","url":"https://clinicaltrials.gov/study/NCT00548184","created_at":"2021-01-18T01:59:43.743Z","updated_at":"2025-02-25T13:09:37.658Z","phase":"Phase 2","brief_title":"Lapatinib and Trastuzumab With or Without Endocrine Therapy","source_id_and_acronym":"NCT00548184 - TBCRC 006","lead_sponsor":"Baylor Breast Care Center","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 overexpression • HER-2 positive + HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 overexpression • HER-2 positive + HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • lapatinib"],"overall_status":"Completed","enrollment":" Enrollment 65","initiation":"Initiation: 05/01/2008","start_date":" 05/01/2008","primary_txt":" Primary completion: 01/01/2011","primary_completion_date":" 01/01/2011","study_txt":" Completion: 01/01/2014","study_completion_date":" 01/01/2014","last_update_posted":"2019-11-07"}]